Kiora Pharmaceuticals Inc. (KPRX)

$2.26 -0.08 (-3.42%)
Market Cap 8.83M
Revenue (ttm) 16.02M
Net Income (ttm) 3.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 22.41%
Debt to Equity Ratio 0.00
Volume 98,700
Avg Vol 50,516
Day's Range N/A - N/A
Shares Out 3.68M
Stochastic %K 56%
Beta -0.89
Analysts Strong Sell
Price Target $12.00

Company Profile

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 224 9600
Address:
332 Encinitas Boulevard, Suite 102, Encinitas, United States
jskstocks
jskstocks Jan. 30 at 12:39 PM
$KPRX this one can run, everything is set up on technical side, if we can hold the $2.20 breakout we are primed. Low float, only 3.5M shares OS, we just need a spark to trigger a frenzy. Sitting on $15M cash, about 2 years burn, one partnered P2 drug, one other P2. The science is differentiated from competition, if the drug works the company is worth 100X they are today. Definitely keeping this one in my portfolio.
0 · Reply
AlwaysLearning72
AlwaysLearning72 Jan. 29 at 9:07 PM
$KPRX up 7% today on over 500k volume. Nice!
0 · Reply
AlwaysLearning72
AlwaysLearning72 Jan. 29 at 7:44 PM
$KPRX lots of volume here today. Interesting. What is in the works?
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 19 at 12:33 PM
$KPRX Current Stock Price: $2.16
0 · Reply
Jake140
Jake140 Dec. 29 at 8:17 PM
$KPRX I'm out...the tax loss is more valuable to me right about now...maybe I'll be back here in February...Good luck to all!
1 · Reply
LeadManagerL
LeadManagerL Dec. 27 at 9:09 AM
$KPRX Capital seems to prefer stability in metrics rather than volatile growth spurts. Forecast reliability has room to improve materially. Durability across environments would extend investor horizons. Execution quality becomes the defining catalyst from here.
0 · Reply
Jake140
Jake140 Dec. 23 at 12:23 PM
$KPRX
0 · Reply
Jake140
Jake140 Dec. 11 at 1:24 PM
$KPRX
0 · Reply
Mr__Man
Mr__Man Dec. 8 at 9:55 PM
$KPRX Moving in AH
0 · Reply
Jake140
Jake140 Dec. 5 at 11:25 AM
$KPRX Morning!
0 · Reply
Latest News on KPRX
Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Jan 27, 2026, 7:00 AM EST - 7 days ago

Retinal Disease Expert Dr. Taiji Sakamoto Joins Kiora Pharmaceuticals' Scientific Advisory Board

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Dec 1, 2025, 6:45 AM EST - 2 months ago

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

Nov 7, 2025, 6:00 AM EST - 3 months ago

Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Oct 30, 2025, 9:00 AM EDT - 3 months ago

Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Oct 15, 2025, 7:00 AM EDT - 3 months ago

Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

Aug 8, 2025, 7:00 AM EDT - 6 months ago

Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

Jul 22, 2025, 8:55 AM EDT - 7 months ago

Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

Jun 3, 2025, 7:00 AM EDT - 8 months ago

Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

May 9, 2025, 7:00 AM EDT - 9 months ago

Kiora Pharmaceuticals Reports First Quarter Results; Initiating Two Phase 2 Trials for Treatment of Retinal Diseases; Cash and Short-term Investments Expected to Fund Operations into Late 2027

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 7:00 AM EDT - 10 months ago

Kiora Pharmaceuticals to Present at The 24th Annual Needham Virtual Healthcare Conference

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Mar 25, 2025, 7:00 AM EDT - 11 months ago

Kiora Pharmaceuticals Reports 2024 Results; Retinal Disease Drug Development Pipeline Continues to Advance; Cash and Short-Term Investments Expected to Fund Operations into 2027

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Mar 12, 2025, 7:00 AM EDT - 11 months ago

Kiora Pharmaceuticals to Present Preclinical Data on KIO-104 for the Treatment of Proliferative Vitreoretinopathy at the ARVO 2025 Annual Meeting

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Feb 13, 2025, 7:00 AM EST - 1 year ago

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Feb 11, 2025, 6:45 AM EST - 1 year ago

Kiora Receives Approval to Initiate KLARITY, a Phase 2 Clinical Trial of KIO-104 for the Treatment of Retinal Macular Edema

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Nov 8, 2024, 7:00 AM EST - 1 year ago

Kiora Pharmaceuticals Reports Third Quarter Results; Retinal Disease Pipeline Advancing Two Phase 2 Studies

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Oct 29, 2024, 6:45 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives Investigational New Drug Approval to Initiate ABACUS-2, a Phase 2 Clinical Trial of KIO-301 for the Treatment of Retinitis Pigmentosa

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Sep 25, 2024, 9:55 AM EDT - 1 year ago

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Bonds still bouncing along

Sep 9, 2024, 4:55 PM EDT - 1 year ago

Bonds still bouncing along

CPLS EYEG HYFI JPST TLT USHY YEAR

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Aug 9, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Jul 30, 2024, 6:45 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Jul 10, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Participate in Jones Healthcare Seaside Summit 2024; Kiora Invites Investors to Submit Questions Following the Conference Presentation

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

DARE

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Jun 25, 2024, 6:45 AM EDT - 1 year ago

Vitreoretinal Surgeon and Key Thought Leader Roger Goldberg, M.D., Joins Kiora Pharmaceuticals' Scientific Advisory Board

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

May 10, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

May 8, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present at The Citizens JMP Life Sciences Conference

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

May 6, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Reports Additional Clinical Data for KIO-301 Showing a Statistically Significant Increase in Brain Activity in the Visual Cortex in Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Apr 5, 2024, 7:00 AM EDT - 1 year ago

Kiora Pharmaceuticals to Present at Upcoming Investor Conferences

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Mar 28, 2024, 6:45 AM EDT - 2 years ago

Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Mar 25, 2024, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Mar 8, 2024, 7:00 AM EST - 2 years ago

Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Jan 31, 2024, 6:40 PM EST - 2 years ago

Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini

Jan 31, 2024, 5:15 PM EST - 2 years ago

Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini

AllianceBernstein Launches Five New Active ETFs

Dec 13, 2023, 7:30 AM EST - 2 years ago

AllianceBernstein Launches Five New Active ETFs

AB BUFC CPLS EYEG TAFL TAFM

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

Nov 9, 2023, 7:18 AM EST - 2 years ago

Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Nov 4, 2023, 12:15 PM EDT - 2 years ago

AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Oct 16, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Oct 3, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Sep 14, 2023, 7:01 AM EDT - 2 years ago

Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

Sep 1, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

Aug 29, 2023, 1:43 PM EDT - 2 years ago

Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Aug 23, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

Aug 22, 2023, 1:06 PM EDT - 2 years ago

Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Webcasts Its Investor Presentation from the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Aug 8, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Aug 3, 2023, 7:00 AM EDT - 2 years ago

Kiora Pharmaceuticals, Inc. and Choroideremia Research Foundation Partner to Advance Novel Choroideremia Treatment

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

Aug 1, 2023, 7:00 AM EDT - 2 years ago

Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors

jskstocks
jskstocks Jan. 30 at 12:39 PM
$KPRX this one can run, everything is set up on technical side, if we can hold the $2.20 breakout we are primed. Low float, only 3.5M shares OS, we just need a spark to trigger a frenzy. Sitting on $15M cash, about 2 years burn, one partnered P2 drug, one other P2. The science is differentiated from competition, if the drug works the company is worth 100X they are today. Definitely keeping this one in my portfolio.
0 · Reply
AlwaysLearning72
AlwaysLearning72 Jan. 29 at 9:07 PM
$KPRX up 7% today on over 500k volume. Nice!
0 · Reply
AlwaysLearning72
AlwaysLearning72 Jan. 29 at 7:44 PM
$KPRX lots of volume here today. Interesting. What is in the works?
0 · Reply
BillionerOfKing
BillionerOfKing Jan. 19 at 12:33 PM
$KPRX Current Stock Price: $2.16
0 · Reply
Jake140
Jake140 Dec. 29 at 8:17 PM
$KPRX I'm out...the tax loss is more valuable to me right about now...maybe I'll be back here in February...Good luck to all!
1 · Reply
LeadManagerL
LeadManagerL Dec. 27 at 9:09 AM
$KPRX Capital seems to prefer stability in metrics rather than volatile growth spurts. Forecast reliability has room to improve materially. Durability across environments would extend investor horizons. Execution quality becomes the defining catalyst from here.
0 · Reply
Jake140
Jake140 Dec. 23 at 12:23 PM
$KPRX
0 · Reply
Jake140
Jake140 Dec. 11 at 1:24 PM
$KPRX
0 · Reply
Mr__Man
Mr__Man Dec. 8 at 9:55 PM
$KPRX Moving in AH
0 · Reply
Jake140
Jake140 Dec. 5 at 11:25 AM
$KPRX Morning!
0 · Reply
TheUnmaker
TheUnmaker Dec. 5 at 2:35 AM
$KPRX I'm in quietly and holding from low 1.80s, strong hands here.
0 · Reply
Jake140
Jake140 Dec. 4 at 12:56 PM
$KPRX
0 · Reply
Mr__Man
Mr__Man Dec. 3 at 7:10 PM
$KPRX worth well over $4.X and probably more with this well tasty new patent
0 · Reply
Mr__Man
Mr__Man Dec. 3 at 7:09 PM
$KPRX This is Hot To Go boys and girls
0 · Reply
Jake140
Jake140 Dec. 3 at 6:38 PM
$KPRX Finally…some positive movement!
0 · Reply
Jake140
Jake140 Dec. 1 at 6:15 PM
$KPRX
0 · Reply
newsfile_corp
newsfile_corp Dec. 1 at 11:47 AM
https://nfne.ws/276367 $KPRX #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Patent #NASDAQ #Investing
0 · Reply
Jake140
Jake140 Nov. 26 at 8:57 AM
$KPRX
0 · Reply
Stmkr
Stmkr Nov. 21 at 3:32 PM
$AZTR $KPRX $LYRA getting hammered every day
1 · Reply
RedDogSailor
RedDogSailor Nov. 20 at 8:19 PM
$KPRX $5.17 cash/share. THREE orphan drugs designations I’ll slowly add and wait for the inevitable pop.
1 · Reply
ViVega1
ViVega1 Nov. 20 at 7:47 AM
$KPRX "Kiora ended the third quarter of 2025 with $19.4 million in cash, cash equivalents, and short-term investments." MC is still about 7 million, management makes a good job it seems. But you can manipulate sp by low volume. That is crazy imo! I'm invested and every time the question with smal biotechs: hold or sell and buy back later? Not sure, may be I stay and sit it out! Can't deny the facts that cash is three times of MC and management works economically. GL
1 · Reply